PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 6/30

$6.68−0.92 (-12.11%)

Close on Nov 13, 2026Market cap $71.71MP/E –Yield –

PharmaCyte Biotech price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

PharmaCyte Biotech's price to sales ratio was 312.3× on Jan 31, 2013.

Period	Period end	Value	Change (pts)
2013	Jan 31, 2013	312.3×	–

Parsed from the XBRL in PharmaCyte Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1500 reverse split on Aug 10, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PMCB.

Advertisement
300 × 250

See a number that looks wrong?